190 related articles for article (PubMed ID: 17598018)
41. Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference.
Okuda M; Yamamoto Y
Clin Lab Haematol; 2004 Jun; 26(3):215-23. PubMed ID: 15163321
[TBL] [Abstract][Full Text] [Related]
42. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
[TBL] [Abstract][Full Text] [Related]
43. Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: relation to bleeding.
Schols SE; van der Meijden PE; van Oerle R; Curvers J; Heemskerk JW; van Pampus EC
Thromb Haemost; 2008 Jan; 99(1):64-70. PubMed ID: 18217136
[TBL] [Abstract][Full Text] [Related]
44. [Cross-mixing test to detect lupus anticoagulant for diagnosis of antiphospholipid syndrome].
Ieko M; Naito S; Yoshida M
Rinsho Byori; 2009 Oct; 57(10):990-8. PubMed ID: 19928497
[TBL] [Abstract][Full Text] [Related]
45. [Renal function and plasma dabigatran level measured at trough by diluted thrombin time assay].
Martinuzzo ME; Duboscq C; Viñuales ES; Girardi B; Penchasky D; Ceresetto J; Stemmelin G; Otero V; Barrera LH; López MS; Otaso JC; Hoyhamburu J
Medicina (B Aires); 2017; 77(1):31-36. PubMed ID: 28140308
[TBL] [Abstract][Full Text] [Related]
46. Life-threatening bleeding in a patient with a lupus inhibitor and probable acquired factor VII deficiency.
Lim S; Zuha R; Burt T; Chacko J; Scott R; Mainwaring CJ
Blood Coagul Fibrinolysis; 2006 Nov; 17(8):667-71. PubMed ID: 17102654
[TBL] [Abstract][Full Text] [Related]
47. Effect of freezing method and storage at -20 degrees C and -70 degrees C on prothrombin time, aPTT and plasma fibrinogen levels.
Alesci S; Borggrefe M; Dempfle CE
Thromb Res; 2009 May; 124(1):121-6. PubMed ID: 19128820
[TBL] [Abstract][Full Text] [Related]
48. Anticoagulation with Intravenous Direct Thrombin Inhibitors in Pediatric Extracorporeal Membrane Oxygenation: A Systematic Review of the Literature.
Kiskaddon AL; Do NL; Williams P; Betensky M; Goldenberg NA
Semin Thromb Hemost; 2023 Oct; 49(7):756-763. PubMed ID: 37643746
[TBL] [Abstract][Full Text] [Related]
49. Monitoring hypocoagulant conditions in rat plasma: factors determining the endogenous thrombin potential of tissue factor-activated plasma.
Nieuwenhuys CM; Feijge MA; Béguin S; Heemskerk JW
Thromb Haemost; 2000 Dec; 84(6):1045-51. PubMed ID: 11154112
[TBL] [Abstract][Full Text] [Related]
50. Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.
Wakui M; Fujimori Y; Katagiri H; Nakamura S; Kondo Y; Kuroda Y; Nakagawa T; Shimizu N; Murata M
J Clin Pathol; 2019 Mar; 72(3):244-250. PubMed ID: 30518630
[TBL] [Abstract][Full Text] [Related]
51. Performance of Platelin LS and dilute Russell's viper venom for the screening of lupus anticoagulant in patients with venous thromboembolism.
Morelli VM; Rodrigues CA; Noguti MA; Matos MF; da Silveira RC; Ribeiro AA; Lourenço DM
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):401-5. PubMed ID: 17581313
[TBL] [Abstract][Full Text] [Related]
52. Effect of gentamicin on heparin activity.
Tyler LS; Rehder TL; Davis RB
Am J Hosp Pharm; 1981 Apr; 38(4):537-40. PubMed ID: 7282683
[TBL] [Abstract][Full Text] [Related]
53. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
54. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase.
Müller J; Freitag D; Mayer G; Pötzsch B
J Thromb Haemost; 2008 Dec; 6(12):2105-12. PubMed ID: 18826387
[TBL] [Abstract][Full Text] [Related]
55. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
[TBL] [Abstract][Full Text] [Related]
56. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers.
Omote M; Asakura H; Takamichi S; Shibayama M; Yoshida T; Kadohira Y; Maekawa M; Yamazaki M; Morishita E; Nakao S; Wada T
Thromb Res; 2008; 123(2):390-5. PubMed ID: 18579183
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients.
Siegmund R; Boer K; Poeschel K; Wolf G; Deufel T; Kiehntopf M
Thromb Res; 2008; 123(1):159-65. PubMed ID: 18433842
[TBL] [Abstract][Full Text] [Related]
58. Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients.
Winkler AM; Tormey CA;
Am J Clin Pathol; 2013 Nov; 140(5):610-22. PubMed ID: 24124139
[TBL] [Abstract][Full Text] [Related]
59. Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants.
Malaeb BS; Gardner TA; Margulis V; Yang L; Gillenwater JY; Chung LW; Macik G; Koeneman KS
Urology; 2005 Oct; 66(4):830-4. PubMed ID: 16230147
[TBL] [Abstract][Full Text] [Related]
60. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
Eikelboom JW; Hirsh J
Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
